GGrantIndex
← Search

Proteomics Shared Resource

$126,409P30FY2023CANIH

Case Western Reserve University, Cleveland OH

Investigators

Linked publications, trials & patents

Trial NCT05340673Trial NCT05198830Trial NCT02590107Trial NCT02535325Trial NCT02451124Trial NCT02419846Trial NCT02417948Trial NCT02392377Trial NCT02388932Trial NCT02383433Trial NCT02375477Trial NCT02354326Trial NCT02345460Trial NCT02342730Trial NCT02337465Trial NCT02327390Trial NCT02319889Trial NCT02307474Trial NCT02287636Trial NCT02252393Trial NCT02181478Trial NCT02179762Trial NCT02163317Trial NCT02158767Trial NCT02153450Trial NCT02135562Trial NCT02131207Trial NCT02129582Trial NCT02129569Trial NCT02129517Trial NCT02129218Trial NCT02128373Trial NCT02108587Trial NCT02100423Trial NCT02084147Trial NCT02082405Trial NCT02081794Trial NCT02079155Trial NCT02073097Trial NCT02073045Trial NCT02071901Trial NCT02070458Trial NCT02070419Trial NCT02055586Trial NCT02037048Trial NCT01973062Trial NCT01959490Trial NCT01959477Trial NCT01954784Trial NCT01954732Trial NCT01951885Trial NCT01939028Trial NCT01928485Trial NCT01894061Trial NCT01408043Trial NCT00991991Trial NCT00970684Trial NCT00961220Trial NCT00956475Trial NCT00952939Trial NCT00949247Trial NCT00945061Trial NCT00941720Trial NCT00941070Trial NCT00939510Trial NCT00918892Trial NCT00918788Trial NCT00918658Trial NCT00918216Trial NCT00910039Trial NCT00909662Trial NCT00908739Trial NCT00908141Trial NCT00907699Trial NCT00905086Trial NCT00900133Trial NCT00899158Trial NCT00899132Trial NCT00898573Trial NCT00898274Trial NCT00897143Trial NCT00892385Trial NCT00873600Trial NCT00873002Trial NCT00866320Trial NCT00856115Trial NCT00853021Trial NCT00842452Trial NCT00809185Trial NCT00796978Trial NCT00795678Trial NCT00769951Trial NCT00769249Trial NCT00752323Trial NCT00740961Trial NCT00736216Trial NCT00735514Trial NCT00733252Trial NCT00732745Trial NCT00732173

Abstract

PROTEOMICS SHARED RESOURCE PROJECT SUMMARY/ABSTRACT The Proteomics Shared Resource (Proteomics SR) is an essential asset to Case Comprehensive Cancer Center (Case CCC) members' research, illustrated by the breadth of scientific program involvement and reflected in the large number of investigators who use this SR. Last year alone, over 120 investigators, 35% of whom were Case CCC members, accounting for 44% of total usage, from all 7 of the Case CCC Programs used the SR. The mission of the Proteomics SR is to provide advanced proteomic and metabolomic technologies and small- molecule analysis, especially for pharmacokinetic (PK) studies, via state-of-the-art instruments, computational resources, and trained staff, to support clinical, translational, and structural biology research. The Specific Aims of the Proteomics SR are to: 1) Provide advanced proteomic and metabolomics technologies and instrument resources to solve unmet needs in cancer research. 2) Develop and apply systems biology tools to solve challenges in analysis and integration of large ‘omics’ datasets. 3) Provide professional education, consultation and training to Case CCC members. At last review, the Proteomics SR was rated Exceptional merit. Throughout the current funding cycle (2012- 2016), the Proteomics SR provided services to 268 registered users, 83 (31%) of whom are Case CCC members, representing all 7 of the Case CCC programs. The Proteomics SR continues to attract new users, and to provide multiple sophisticated proteomic techniques and technique-specific training to investigators' cancer-related projects. The SR has also developed new technologies and bioinformatics tools that directly facilitate Case CCC members' research, including a global metabolomic and lipidomic platform that will complement both targeted metabolomics and global proteomic experiments. The Proteomics SR consists of two sites; the first site was established at the Cleveland Clinic (CC) Lerner Research Institute (LRI) in 1999 and the second site, the Center for Proteomics & Bioinformatics (CPB) at Case Western Reserve University (CWRU) in 2005. This multi-site Shared Resource, jointly supported and managed by the Case CCC, the CWRU School of Medicine (SOM) and CC, provides access to a full spectrum of proteomic and metabolomic technologies. The services of the Proteomics SR are essential for enhancing the quality of the science in the Case Comprehensive Cancer Center.

View original record on NIH RePORTER →